Skip to main content
Premium Trial:

Request an Annual Quote

Accler8 s Losses Widen in Q1; BACcelr8r Promised in 2006

NEW YORK, Dec. 16 (GenomeWeb News) - Accelr8 Technology today said that despite quadrupling its total revenue for the first fiscal quarter for 2006, net losses widened.


The company said total revenues for the three months ended Oct. 31 increased to $86,388 from $21,724 in the year-ago period


Net loss for the quarter increased 51 percent to $772,000, or $.08 per share, from $509,800, or $.05 per share, year over year, the Denver-based company said.


The company reported research and development expenses of $573,000 for the quarter, a 182-percent increase over the $203,000 reported for the same quarter last year. The increase is attributed to the development of the BACcelr8r diagnostic system.


Accelr8 expects to complete studies on materials and processes for the system and begin selling it in fiscal 2006, the company said.


Acceler8 reported cash and cash equivalents of $4.9 million on hand as of Oct. 31.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.